Počet záznamov: 1
busulfán
SYS d002066 LBL 00000nz--a2200000o--4500 005 20250606213844.5 008 990101|||anznnbabn-----------|-a|a------ 040 $b slo $a DNLM $d BA006 065 $a D02.033.455.125.125 065 $a D02.455.326.146.100.050.500.100 065 $a D02.886.645.600.055.050.510.100 066 $a 01 $c 03 150 $a busulfán $x AA $x AD $x AE $x AG $x AI $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $2 slo 450 $w v $a Busulphan $2 eng 550 $7 sllk_us_auth*d000477 $Y Alkylating Agents $w P $a činidlá alkylačné 550 $7 sllk_us_auth*d007166 $Y Immunosuppressive Agents $w P $a imunosupresíva 550 $7 sllk_us_auth*d018906 $Y Antineoplastic Agents, Alkylating $w P $a antineoplastiká alkylačné 550 $7 sllk_us_auth*d019653 $Y Myeloablative Agonists $w P $a agonisty myeloablácie 680 9-
$i An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. $2 eng 750 -2
$a Busulfan $2 eng 980 $x M
Počet záznamov: 1